+34 620 10 75 37info@nanbiosis.com

Nanbiosis

U1. Protein Production Platform Unit (PPP)

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB

Order request

Description

The PPP Unit is at the Institute of Biotechnology and Biomedicine of the Autonomous University of Barcelona (IBB-UAB). It counts with the necessary facilities for the design, production, and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, led by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer a “tailored” service for the design, production, and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic, X-ray crystallography, and Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, another with all the necessary equipment for molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit has implemented the ISO9001 certification for standard quality control system.

IQNet ISO 9001:2015 Certification PPP

AENOR ISO 9001:2015 Certification PPP

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
PI15/00272 Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. Instituto de Salud Carlos III Participant
BIO2013-41019-P ENGINEERING OF PROTEIN NANOPARTICLES FOR THE DIRECT DELIVERY OF THERAPEUTIC PROTEINS AND NUCLEIC ACIDS MINECO Participant
2014SGR-132 Basic and Applied Microbiology AGAUR Participant
BIO2016-76063-R DEVELOPMENT OF NONOSTRUCTURED PROTEIN TOXINS AND POISONS FOR THE TREATMENT OF CXCR4 + CANCERES MINECO Working package
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant
Marato 416/C/2030TV32013-132031 Genotoxic nanoparticles targeting colorectal cancer stem cells Marato TV3 Participant

Publications


2016

  • Corchero J.L. Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers. Applied Microbiology and Biotechnology. 2016;100(2):559-569.
  • Saccardo P., Corchero J.L., Ferrer-Miralles N.. Tools to cope with difficult-to-express proteins. Applied Microbiology and Biotechnology. 2016;:1-9.
  • Torrealba D., Seras-Franzoso J., Mamat U., Wilke K., Villaverde A., Roher N. et al. Complex particulate biomaterials as immunostimulant-delivery platforms. PLoS ONE. 2016;11(10)
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
  • Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
  • Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies are produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1)
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7)
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U1

04 Apr

Protein-only Materials offer a new hope in colorectal cancer treatment

Breakthrough colorectal cancer treatment unveiled by NANBIOSIS Units promises enhanced precision & efficacy in targeted cancer therapies. March 2024, UAB/Institut de Recerca Sant Pau/CIBER-BBN (Barcelona) As we leave World Colorectal Cancer Day 2024 behind, marked on March 31st, there have been significant highlights in cancer treatment, a field in which targeted therapies are playing a crucial role. In this context, researchers from the Nanobiotechnology team, at the Institut de Biotecnologia i de Biomedicina from Universitat Autònoma de Barcelona, led by Prof. Antonio Villaverde, in collaboration with the Oncogenesis and Antitumor Drugs team led by Prof. Ramón Mangues at Institut d[...]

05 Mar

New immunization research for SARS-CoV-2 with the collaboration of NANBIOSIS

This novel immunization platform, recently published in ACS, triggers potent antivirus response, promising efficient and cost-effective vaccination. March 2024, UAB/Vall d’Hebron Research Institute/CIBER-BBN (Barcelona) The battle against infectious diseases demands innovative solutions. The world is especially aware of this fact after facing threats such as the SARS-CoV-2 pandemic. In a very recent publication in ACS Materials Letters, researchers from the Universitat Autònoma de Barcelona (UAB) and Hospital de Sant Pau, both within the CIBER-BBN, have achieved a significant milestone in vaccine development. Their study, conducted in partnership with international teams as well as NANBIOSIS, has introduced a novel immunization approac[...]

27 Dec

NANBIOSIS U1_Protein Production Platform expands its facilities at the Autonomous University of Barcelona, strengthening its capabilities.

NANBIOSIS Unit 1 Protein Production Platform (PPP) of CIBER-BBN and UAB, has taken a significant step towards enhancing its service capabilities in the field of recombinant protein production and purification. Until now, due to space constraints at the Institute of Biotechnology and Biomedicine (IBB), U1’s activities were confined to half of a small laboratory. However, thanks to the ongoing commitment of the center to bolster the PPP’s activities, this unit has gained access to a laboratory, along with an office, exclusively designated for the platform within the IBB premises, creating an optimal environment for the process of protein production and[...]

20 Dec

Good News! Protein Nanoparticles with a New Ligand Select and Destroy Tumor-associated Fibroblasts”

With the participation of two units of NANBIOSIS ICTS and the expertise of the scientists managing these units The study, fruit of the collaboration between the Nanotechnology group of the Institute of Biotechnology and Biomedicine (IBB-UAB), led by Prof. Antonio Villaverde, and the Oncogenesis and Antitumor Drugs group of the Sant Pau Research Institute, led by Dr. Ramon Mangues, both members of CIBER-BBN, has made significant progress by identifying the natural ligand PDGFD as an effective tool to target protein nanoparticles to tumor-associated fibroblasts that overexpress the PDGFR-β receptor. Given the relevance of the discovery, this technology has been intellectually[...]

30 Nov

NANBIOSIS U1 PPP invited to PEGS, the Protein & Antibody Engineering Summit

*Image explained by Merce Márquez Martínez, Coordinator of NANBIOSIS U1 The NBT group and Unit 1 of NANBIOSIS (Protein Production Platform, PPP), from CIBER-BBN and IBB-UAB, participated in the 15th PEGS Europe conference held in Lisbon from November 14th to 16th. PEGS, or the Protein & Antibody Engineering Summit, is a prestigious conference, organized by the Cambridge Healthtech Institute (CHI), focusing on protein engineering and its applications in drug discovery, development, and delivery. This conference serves as a valuable platform for knowledge exchange among researchers, scientists, industry experts, and professionals in the field of protein science. From left to right,[...]

08 Nov

Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.

2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed audience. On Tuesday 7 EHD and BBN sessions will specific for each area in separate rooms (with common coffee break). Posters of both areas were on display in the exhibit hall throughout the entirety of the Annual Meeting. Moreover, at the “Posters & beers” session (Monday[...]

23 Oct

NANBIOSIS U1 at UAB Innovation Fair

On October 17, 2023, the NANBIOSIS U1 of Protein Production Platform PPP, took part in the UAB Innovation Fair, where various research groups, spin-offs, service providers, research centers, and companies gathered to foster networking opportunities. This event proved highly advantageous for the PPP, as it not only facilitated the identification of potential new clients but also paved the way for collaborative efforts aimed at enhancing and refining the final product offered by the PPP. PPP NANBIOSIS U1 Scientists at PPP stand at the Fair: Neus Ferrer, Scientific Director; Rosa Mendoza, Laboratory Manager, and Mercedes Marquez, Scientific Coordinator. The UAB Innovation[...]

28 Sep

Nanoligent raised €2.8 M and completed Seed round financing with support of i&i Biotech Fund

September 27th 2022 – Nanoligent SL, a Spanish biotech company specialized in the development of cancer treatments based on unique protein conjugates, today announces the completion of a Seed financing round of total € 2.8 M. The final closing of the Seed round consists of € 1 M investment by i&i Biotech Fund I (i&i Bio), an early-stage Life Science fund with teams in Luxemburg and Prague which is backed by the European Investment Fund. i&i Bio joined previous Nanoligent investors, Italian Angels for Growth, the largest network of business angels in Italy, and AVANTECA Partners, a Swiss privately held[...]

U1-Protein Production Platform - PPP
Read More

U2. Custom Antibody Service Unit (CAbS)

U2 CAbS-hybridoma clone

U2. Custom Antibody Service (CAbS)

  • Scientific Director: Prof. Pilar Marco pilar.marco@cid.csic.es
  • Scientific Coordinator: Dr. Nuria Pascual npdqob@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC

IQAC CSIC

Order request

Description

The facility is located in the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC; Barcelona). It is equipped with a laboratory for the development and production of monoclonal antibodies. The laboratory is fully equipped for obtaining, selecting and storing monoclonal antibody producing hybridomas. In addition, the facility has infrastructure for the production of polyclonal antibodies, as well as laboratories for the synthesis of bioconjugates, haptens, the purification of antibodies and the performance of immunoassays. In addition to the above mentioned equipment, the IQAC-CSIC provides animal husbandry facilities and a unit for the synthesis of organic molecules.

The equipment consists in an inverted phase contrast microscope with a camera, two Class II laminar flow biological safety cabinets, two CO2 incubators, a bioreactor for hybridoma culture, and tangential filtration unit for purification of the antibodies produced in the culture. Among the items of available equipment it should be highlighted a spotter for selection of high antibody producing cell lines and an automated ELISA microplate washer an ELISA reader, two AKTA Prime Liquid chromatography systems for antibody purification, plus standard equipment (centrifuges, fridges, liquid nitrogen containers, autoclave, baths, and vacuum equipment) and all the necessary routine laboratory apparatus.Cabs also has access to a fully equipped chemistry laboratory for the synthesis of haptens and immunoreagents.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
PIE1400061 Molecular links between diabetes and neurodegenerative diseases ISCIII Oberver
2014SGR1484 Consolidated Research Group Generalitat de Catalunya Participant
FP7-614168 Real time monitoring of SEA contaminants by an autonomous Lab-on-a-Chip biosensor (SEA-on-a-CHIP) European Commission Oberver
CI16-00031 Caixa Impulse A new approach for the detection of Pseudomonas aeruginosa CaixaBank Participant
MSCA-ITN2015-675412 New Diagnostics for Infectious Diseases European Commission Participant
TECCTP15-1-0011 Ajuda acreditació Tecnio del grup Nb4D ACCIÓ: Generalitat de Catalunya Others

Publications


2016

  • Roncador G., Engel P., Maestre L., Anderson A.P., Cordell J.L., Cragg M.S. et al. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. 2016;8(1):27-36.
  • Pastells C., Pascual N., Sanchez-Baeza F., Marco M.-P.. Immunochemical Determination of Pyocyanin and 1-Hydroxyphenazine as Potential Biomarkers of Pseudomonas aeruginosa Infections. Analytical Chemistry. 2016;88(3):1631-1638.
  • Salvador J.-P., Marco M.-P.. Amperometric Biosensor for Continuous Monitoring Irgarol 1051 in Sea Water. Electroanalysis. 2016;28(8):1833-1838.

News U2

21 Jun

Prof. Pilar Marco takes helm of CIBER-BBN: Leading the future of Bioengineering, Biomaterials, and Nanomedicine

Barcelona, June 21, 2024 – Prof. Pilar Marco has been appointed as the new head of the Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN) thematic area at the Centro de Investigación Biomédica en Red (CIBER). This prestigious appointment was confirmed during the CIBER Governing Board meeting held on June 20, 2024. Prof. Marco succeeds Ramón Martínez, bringing a wealth of expertise and a distinguished track record in biomedical research for more than a decade. Prof. Marco is a research professor at the Consejo Superior de Investigaciones Científicas (CSIC), specifically at the Institute of Advanced Chemistry of Catalonia (IQAC) in Barcelona. Additionally, s[...]

28 Feb

The fight against rare respiratory diseases: New hope in detection and treatment

Researchers from IQAC-CSIC advance towards faster detection and treatment of cystic fibrosis and rare respiratory diseases, improving patient outcomes. 28 February 2024, IQAC-CSIC (Barcelona) Cystic Fibrosis (CF) is a progressive autosomal recessive disease. It is caused by a mutation in the gene encoding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, disrupting its exocrine activity. While CF affects various organs, its impact on the lungs is particularly severe. This disease leads to the accumulation of thick, sticky mucus, obstructing airways and trapping bacteria, resulting in significant infections and extensive lung damage. Consequently, individuals with CF are highly susceptible to respiratory[...]

24 Nov

From the molecule to the bioassay by Custom antibody service (CAbS)-NANBIOSIS U2 as a PTI+Global Health Infraestructure

During 20-22 of November 2023, the III PTI+Global Health Scientific Conference were held in the Center for Human and Social Sciences, in Madrid. In March 2020, the CSIC (Spanish National Research Council) launched the the Interdisciplinary Thematic Platform (PTI) on Global Health to bring together research teams and enhance knowledge about the new coronavirus SARS-CoV-2, which caused the pandemic. The PTI has mobilized and coordinates more than 400 scientists from 50 CSIC institutes in all areas. The annual PTI+Global Health Scientific Conference are a meeting space where the results of the research carried out in the laboratories can be shown[...]

08 Nov

NANBIOSIS sesion in the CIBER-BBN and CIBEREHD annual meeting. SAFE-N-MEDTECH Project: Outcomes and Future Prospects.

The annual conference of the scientific áreas of CIBER (the most important Centre for Biomedical Research in Spain) are hotly awaited every year for the CIBER community as a foro to be updated about emerging key technologies and discuss about research lines and results, find new opportunities to collaborate and join efforts towards common objectives. Moreover, this year, the Annual Conference of CIBER-BBN (Bioengineering, Biomaterials and Nanomedicine) has been organized as a collective event scheme together with the scientific area of CIBEREHD (Digestive and Liver Diseases). Both areas have already shared experiences of collaborative projects, demonstrating the complementarity of their fields.[...]

20 Oct

The importance of bacterial Quorum Sensing (QS) research recognised in the Princesa of Asturias Awards

Today, Bonnie Bassler, Jeffrey Gordon, and Peter Greenberg are receiving the Princess of Asturias Award for their contribution to the knowledge of the role of the human microbiome and the bacteria Quorum Sensing. Targeting Quorum Sensing allows understanding of bacteria behaviour and pathogenesis, but also developing new therapeutic and diagnostic strategies for infectious diseases. Bonnie Bassler has shown how small chemical signals are involved in such a communication process. Peter Greenberg was one of the first scientists who assigned the term Quorum Sensing (QS) to such a sophisticated system used by bacteria to communicate and synchronize behavior. He was involved[...]

15 May

New look of Nb4D – CAbS (NANBIOSIS U2) “Revolutionising Diagnosis”

Nb4D has a new look on line! Nb4D Group (of IQAC-CSIC and CIBER-BBN) has lunched a new website “Revolutionsising Diagnosis“ with the aim to facilitate a faster and easier navigation througth their “pioneering research to develop new diagnostic and therapeutic approaches” and their solutions and expertise to help researchers and companies. Antibodies, bioreceptors, hapten design and synthesis, immunoanalytical method development, new ivd tools, surface functionalization, therapeutic antibodies and much more knowledge and expertise revolutionising diagnosis. The new website contains a page for CAbS-NANBIOSIS. Custom Antibody Service (CAbS), unit 2 of the ICTS NANBIOSIS[...]

28 Feb

Rare diseases international day 2023: some NANBIOSIS contributions

Today is the international day of rare diseases, a day to raise awareness and instigate change for people living with a rare disease. From NANBIOSIS we want to sume to this celebration and higtligh our commitment to helping people with rare diseases through research. Dr. Ibane Abasolo, Scientific Director of NANBIOSIS U20, was at the WORLDSymposia conference last week in Orlando (FL, USA), where the latest advances in preclinical study and clinic of lysosomal storage diseases were explained. There, she presented the results obtained in the Smart4Fabry project coordinated by the CIBER-BBN where nanoliposomes were developed for the treatment of[...]

27 Feb

New method for the detection of RNA viruses such as SARS-CoV-2

Several CIBER-BBN groups at the University of Barcelona, the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) and the Institute of Nanoscience and Materials of Aragon (INMA) —a joint institute of the CSIC and the University of Zaragoza (UNIZAR)— have developed a new method for detecting RNA viruses based on the technology of using probes that form triplex structures. This innovative methodology opens up new options to detect viruses such as SARS-CoV-2, the influenza A (H1N1) virus or the respiratory syncytial virus (RSV), a pathogen that affects newborns and requires differential diagnostic care. This[...]

U2-Custom Antibody Service (CAbS)
Read More

U3. Synthesis of Peptides Unit

U3. Synthesis of Peptides Unit

  • Scientific Director: Dr. Miriam Royo miriam.royo@iqac.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC
IQAC CSIC

Order request

This Unit is coordinated by the Multivalent Systems for Nanomedicine goup at IQAC-CSIC and has the equipment necessary to provide services of synthesis of peptides at different scales (mg to g), purification, characterization, and post-synthesis modification, such as, conjugation to proteins and fluorescent. It counts with laboratories for synthesis and other to carry out modification of the peptides during and post synthesis labels. Also counts with a laboratory equipped with several preparative and analytical chromatography systems for purification and characterization. This facility benefits from the wide experience of Dr. Fernando Albericio an Dra. Miriam Royo in the design and synthesis of peptides with specific biological activity and the introduction of modifications necessary for these peptides to be bound to therapeutic nanoconjugates and other molecules, either to take advantage of the pharmacological activity of the peptide itself or to facilitate the introduction of nanoconjugates or other molecules into the cells in order to reach the therapeutic target. Its location allows the access to the rest of services of the IQAC-CSIC.

Active projects

Title Fundin: Organism Call: Funding source Role
ICTS-2017-10-CIBER-2 Acquisition and istallation of infrastrucuture to complemntUnis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivoExperiment Ministerio de Economía, Industria y Competitividad (MINECO) Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt) Coordinator
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U3

08 Nov

Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.

2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed audience. On Tuesday 7 EHD and BBN sessions will specific for each area in separate rooms (with common coffee break). Posters of both areas were on display in the exhibit hall throughout the entirety of the Annual Meeting. Moreover, at the “Posters & beers” session (Monday[...]

20 Jan

New nanoarchitectonics of RGD peptide developed using quatsomes as robust tool in tissue engineering.

Researchers of three groups of CIBER-BBN at CSIC and IBEC, have created a versatile platform based on hierarchically nanostructured RGD peptide using quatsomes, with proved enhanced cell adhesion. These findings, which arose within the framework of the intramural project of CIBER-BBN “Molecular Biointerfaces for cell guidance” (DynaMo4Vasc), open new possibilities for tissue engineering. The participation of two NANBIOSIS units were acknowledged in the publication of the research results: the synthesis of RGD derivatives were performed at NANBIOSIS U3 “Synthesis of peptides unit” of CIBER-BBN at IQAC−CSIC.  And the design and characterization of quatsomes were done at U6 of NANBIOSIS “Biomateria[...]

15 Nov

Happy Day of Chemistry! The role of Chemistry in a sustainable research in health

Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

28 Feb

Fabry Desease in the Rare Disease Day: A New Hope

WHY DO CELEBRATE TODAY THE INTERNATIONAL #RareDiseaseDay? 29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives.  Since 2008 thousands of events happen every year all around the world and around the last day of February with the aim of improving equity and reducing stigmatization for people who live with more than 6,000 rare diseases. WHAT ARE RARE DISEASES Rare diseases are pathologies or disorders that affect a small part of the population (less than 5 per 10,000 inhabitants) and[...]

03 Feb

Multivalent self-assembled platforms for the delivery of chemotherapeutic drugs

Twenty years ago, the 4 February was declared World Cancer Day with the global challenge of cancer would not be forgotten. Since then, huge progress has been made to understand, prevent, diagnose, and treat cancer. NANBIOSIS as an ICTS (Singular Scientific and Technical infrastructures) for biomedical research plays a very important role in the fight against cancer. Dr. Miriam Royo, who leads NANBIOSIS unit 3 of Synthesis of Peptide, explains one of the projects in which the ICTS is involved in relation with cancer therapy. The improvement of solubility and stability of clinically approved chemotherapeutic drugs still represent a big[...]

26 Feb

A more effective nanomedicine has been developed for the treatment of Fabry rare disease.

28 February: International Rare Disease Day This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work.The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future.The new drug improves on current treatments and helps reduce costs and improve patients’ quality of life. Barcelona, 26 February 2021.- The advance of nanomedicine opens up new possibilities in the development of drugs, such as the one recently developed for the rare disease Fabry, with improved efficacy compared to existing[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

U3-Synthesis of Peptides Unit
Read More

U6. Biomaterial Processing and Nanostructuring Unit

Ciber bbn

U6. Biomaterial Processing and Nanostructuring Unit

    • Scientific Director: Prof. Nora Ventosa ventosa@icmab.es 
    • Scientific Coordinator: Dr. Mariana Köber mkober@icmab.es
    • Technical Coordinator: José Amable Bernabé jabernabe@icmab.es
    • Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
    • Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
    • Phone: +34 935 801 853
    • Fax: +34 935 805 729
    • Web: ICMAB

ICMAB CSIC

Order request

Description

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Prof. Nora Ventosa, current director of NANOMOL Group, which is a research group with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties. It gathers several laboratories, perfectly equipped, to perform the mission of this facility: the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure. One example of Key-Enabling-Technology (KET) available in this unit is a simple one-step methodology, DELOS-SUSP, based on the use of compressed fluids (CF), such as CO2, to prepare particulate materials with precise and reproducible structural characteristics at micro-, nano- and supramolecular levels (size, shape, internal structural gradients, supra­molecular organization and crystalline purity). This example shows one of the singularities of this unit is that counts with CF–based plants at different scales, from mL to L, which allow process development by QbD and process scale-up.
The NANBIOSIS Unit 6 is works under the ISO9001 certification for standard quality control system
 

 

 

U6. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
PI15/00272 Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. Instituto de Salud Carlos III Participant
H2020-MSCA-ITN-2014-642196 Integrated self-assembled SWITCHable systems and materials: towards responsive organic electronics - a multi-site innovative training action i-Switch Unión Europea H2020 Participant
2014 SGR 17 Consolidation Research Group: Molecular Nanociènciai Materials Orgànics (NANOMOL) Generalitat de Catalunya Participant
CTQ2013-40480-R Molecular Bio- and Electro-active materials for the improvement of health and social well-being (Be-Well) MICINN Participant
FP7-PEOPLE-2013-ITN nº 607721 Nanochemistry of molecular materials for 2-photon functional applications. Nano2Fun Unión Europea Participant
MAT2013-50036-EXP Cell Surface Vessel Engineering Using Dynamic Molecular Bioinfecting (DYNAMO) MINECO Participant
RTC-2016-4567-1 Nanocapsules containing active ingredients for the topical treatment of dermatological diseases (NANO4DERM) MINECO Participant
RTC-2014-2183-S Application of Quatsomes technology for the development of a new range of perfumed softeners with lower environmental impact MINECO Participant
201260E080 Self-assembly, Nanostructuring and Processing of Functional Organic Molecules and their Applications Ministerio de Ciencia e Innovación Participant
MAT2016-80826-R Molecular materials and supramolecular organizations for therapy, diagnosis and tissue engineering (MOTHER) MINECO Participant
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

  • Munoz-Gomez J.L., Monteagudo E., Lloveras V., Parella T., Veciana J., Vidal-Gancedo J.. Optimized polarization build-up times in dissolution DNP-NMR using a benzyl amino derivative of BDPA. RSC Advances. 2016;6(32):27077-27082.
  • Cordoba A., Hierro-Oliva M., Pacha-Olivenza M.A., Fernandez-Calderon M.C., Perello J., Isern B. et al. Direct Covalent Grafting of Phytate to Titanium Surfaces through Ti-O-P Bonding Shows Bone Stimulating Surface Properties and Decreased Bacterial Adhesion. ACS Applied Materials and Interfaces. 2016;8(18):11326-11335.
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.

News U6

01 Mar

Reaching for the unreachable: New efforts to treat Lysosomal Storage Diseases

NANBIOSIS researchers pioneer novel treatments for Lysosomal Storage Diseases utilizing extracellular vesicles and liposomes, offering hope to patients. 1 March 2024, Vall d’Hebron Research Institute/ICMAB-CSIC (Barcelona) Lysosomal Storage Diseases (LSDs) encompass a group of rare disorders caused by mutations in lysosomal proteins. These mutations can lead to dysfunctional proteins responsible for breaking down cellular materials, resulting in the accumulation of deposits. Such accumulations can manifest in various neurological symptoms, ranging from progressive neurodegeneration to severe cognitive impairment. Often emerging in childhood, LSDs tragically culminate in premature death for many patients. Currently, up to 14 subtypes of LSDs can be treated[...]

21 Feb

The NABIHEAL Project Pioneers Wound Healing with New Biomimetic Matrices

Nearly 40 scientists across 7 countries are pioneering this breakthrough in wound healing using a nobel and affordable bio-inspired, anti-bacterial matrix. In addition to the vast consortium, the project also comprises 5 small and medium-sized enterprises (SMEs) and 9 academic institutions. These were convened last February at the University of Granada to share insights, progress, and strategies. According to an article published by UGR at the beginning of this month, about 40 researchers involved in the project have attended a meeting to share results and progress. The Horizon Europe project NABIHEAL, coordinated by the Biomedical Research Networking Center (CIBER) at[...]

27 Oct

Technical seminar on materials characterisation equipment

The Service-SOFT/U6 Nanbiosis ICTS (of CIBER-BBN and ICMAB-CSIC) together with the company NANE are organising a technical seminar on materials characterisation equipment. In this seminar, different techniques for the characterisation of particulate materials such as DLS, NTA, Laser Diffraction, Morphology will be discussed. Limited places. You can register at this link Link to the program: here Date: 08th of November Place: Institute of Materials Science of Barcelona (ICMAB) -CSIC – Conference room[...]

12 May

NABIHEAL project launches website

The website for NABIHEAL, an EU-funded Horizon Europe project developing biomaterials for complex wound healing, is now online. The Horizon Europe project NABIHEALi project is coordinated by the Center for Biomedical Research Network (CIBER) at the Institute of Materials Science of Barcelona (ICMAB-CSIC). This project will apply one the “Cutting Edge Biomedical Solutions” of NANBIOSIS for the preparation of different nanoestructures with antimicrobial properties, required for the development of the final multifunctional wound healing biomaterials. This case will gather the expertise of two NANBIOSIS unit: NANBIOSIS U6 will produce and characterize these nanoestructures with antimicrobial properties, which will be tested in NANBIOSIS U16. Find out mor[...]

21 Mar

A discovery in one of the most aggressive cancers will allow more efficient diagnosis

The extracellular vesicles secreted by triple-negative breast cancer stem cells are markers of lung metastasis, according to a study carried out by researchers at CIBER. The work has been carried out by researchers from various CIBER-BBN groups (Bioengineering, Biomaterials and Nanomedicia), and CIBERONC (CIBER area focused on cancer) has participated in it. The research has been led by Joaquín Seras, from the Vall d’Hebron Research Institute (VHIR), a specialist in targeted drug therapies. Physicochemical EVs characterization and all the in vivo studies were performed by NANBIOSISunits of CIBER, specifically NTA analysis was carried out at Unit 6 of Biomaterial Processing[...]

20 Mar

Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior

Doctor Marc Martínez from the Nanomol-Bio group – NANBIOSIS U6 from CIBER-BBN at ICMAB-CSIC, defended his PhD thesis “Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior” on 9 March 2023 at ICMAB. he PhD thesis was supervised by Imma Ratera, Judith Guasch and Nora Ventosa from the Nanomol-Bio group at ICMAB-CSIC. Ana Paula Candiota Silveira, Scientific Coordinator of NANBIOSIS U25 was part of the Committee that evaluated the Thesis tooghether with Jesús Martínez de la Fuente, Instituto de Nanociencia y Materiales de Aragón (INMA-CSIC) (President),  and Anna Lagunas Targarona, Institut de Bioenginyeria de Catalunya (IBEC) (Vocal). As[...]

02 Feb

Advancing a novel nano-pharmaceutical towards clinical translation

Prof Nora Ventosa, Scientific Director of NANBIOSIS U6 “Biomaterial Processing and Nanostructuring Unit” from CIBER-BBN and ICMAB-CSIC) is hosting the Lecture on nano-pharmaceuticals: “Advancing a novel nano-pharmaceutical towards clinical translation” by Elisabet González, from Nanomol-Bio Group of ICMAB-CSIC and CIBER-BBN Monday, 13 February 202312 PM – 15 PMICMAB – Sala d’Actes Carles Miravitlles and ONLINE Registration and futher information Abstract: Nano-pharmaceuticals have the potential to drive the scientific and technological uplift, offering great clinical and socio-economic benefits to the society in general, industry and key stakeholders and patients. However, the translation of nano-pharmaceuticals from lab bench to an advanced stage of[...]

20 Jan

New nanoarchitectonics of RGD peptide developed using quatsomes as robust tool in tissue engineering.

Researchers of three groups of CIBER-BBN at CSIC and IBEC, have created a versatile platform based on hierarchically nanostructured RGD peptide using quatsomes, with proved enhanced cell adhesion. These findings, which arose within the framework of the intramural project of CIBER-BBN “Molecular Biointerfaces for cell guidance” (DynaMo4Vasc), open new possibilities for tissue engineering. The participation of two NANBIOSIS units were acknowledged in the publication of the research results: the synthesis of RGD derivatives were performed at NANBIOSIS U3 “Synthesis of peptides unit” of CIBER-BBN at IQAC−CSIC.  And the design and characterization of quatsomes were done at U6 of NANBIOSIS “Biomateria[...]

U6-Biomaterial Processing and Nanostructuring Unit
Read More

U7. MicroFab & Microscopy Unit

Ciber bbn

U7. MicroFab & Microscopy Unit

 

Order request

Description

The MicroFab & Microscopy Platform is part of the institute’s long-term strategic plan to create new Core Facilities in nanofabrication and bionanocharacterization. Currently, the platform is an accessible and versatile research facility featuring 150m2 of class 10,000 cleanroom space and laboratories offering state-of-the-art equipment for the fabrication and characterization of micro- and nanodevices and structures. Our aim is to facilitate advanced research by providing services in the fields of nanoscience and nanotechnology for all academic and industrial researchers. Some of the many areas of application include nanobioengineering, BioMEMS, materials science, tissue engineering, optic and biomaterials. IBEC’s Nanotechnology Platform offers scientific and technological support that includes the design, development and analysis of devices, materials, and processes, so that academic researchers and companies alike may use the platform to develop their innovative ideas.

Active projects

TitleFundin: OrganismCall: Funding source Role
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Partner
PICCOLO-732111Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision supportEuropean Commission-H2020H2020-ICT-2016-1Partner
0624_2IQBIONEURO_6_EPromotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseasesEuropean Union Interreg : European Territorial Co-operationPOCTEP Interreg España-PortugalPartner

Other projects

RefTitleFunding OrganismUnit Role
TEC2015-70104-PMicroscrofidic 3D platform of Neuronal culture compartmentalized for the study of neurological diseasesMINECOOthers
COMRDI15-1-0013-09Advancecat: acceleradora pel desenvolupament de terapies avançadesACCIÓParticipant

Publications

2016

  • Lagunas A., Tsintzou I., Vida Y., Collado D., Perez-Inestrosa E., Pereira C.R. et al. Tailoring RGD local surface density at the nanoscale toward adult stem cell chondrogenic commitment. Nano Research. 2016;:1-13.

News U7

24 Oct

NANBIOSIS U7 at the 15th IBEC Symposium October 2022

The MicrofabSpace and Microscopy Characterization Facility of IBEC, U7 unit of Nanbiosis, presented a stand and posters in the 15 edition of the annual IBEC’s Symposium which took place last October 19th in Barcelona. Researechers of this facility showed new microfabrication processes and microscopy tools, to worldwide researchers in the field of bioengineering. The MicroFabSpace and Microscopy Characterization Facility is one of the most experienced services in the IBEC’s Core Facilities. With a cleanroom research space, specialized in the microfabrication and characterization of micro-structured devices focussed on bioengineering and a microscopy space specialized in the characterization of biological samples, it[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

16 Sep

Microfluidic devices: The process of development

The development of microfluidic devices is very significant for in-vitro diagnostic devices, biomarkers and organ-on-a-chip applications. The techniques, the materials and the equipment used for the fabrication of these devices, are as important as the strategy followed to obtain them. And at the Nanotechnology unit of NANBIOSIS U7– (MicrofabSpace and Microscopy Characterization Facilities of IBEC), we own the tools, the know-how and the expertise to accomplish such a goal. We regularly guide the process of design, in collaboration with the final user, we customize the technology needed to get the product and complete the fabrication of the microfluidic device, drawing[...]

16 May

The importance of Nanomedicine and Bioengineering to address health challenges

Josep Samitier, Coordinator of the Nanomedicine Platform (NanoMed) and Director of IBEC, as well as Scientific Director of NANBIOSIS unit 7 of Nanotecnology, of IBEC and CIBER-BBN, particiated in the XIV Annual Conference of Biomedical Research Technology Platforms was held on 11 and 12 May. The Conference counted with the presence of relevant public and private sector actors, and more than 700 registered participants. During the opening ceremony, was opened, among others, by the Minister of Science and Innovation, Pedro Duque, it was precisely emphasized the importance of investment in science and technology. In the words of Josep Samitier: “The healt[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

22 Jul

The Scientific Director of NANBIOSIS Unit 7, awarded with the Narcís Monturiol medal for his contribution to science and technology

The Catalan Government announced yesterday the Narcís Monturiol Medal award for scientific and technological merit to the Director of NANBIOSIS Unit 7 Nanotechnology Unit from CIBER-BBN and IBEC, Josep Samitier Martí, for his contribution to the development of the Catalan system of science and technology. The Narcís Monturiol Prize was established by the Generalitat of Catalonia in 1982, in honor of the Catalan scientist and inventor Narciso Monturiol, to award the people and entities that have made an outstanding contribution to the scientific and technological progress of Catalonia. It is awarded in the form of medals and plaques. The medals[...]

08 Jun

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]

04 Dec

“Tips and tricks to achieve good results at the bench”

The IBEC Core Facilities team, coordinating NANBIOSIS U7 Nanotechnology Unit has celebrated the 6th edition of the Workshop “Tips and tricks to achieve good results at the bench”. This workshop is focused on fundamental basic aspects of working in a Chemistry/Biology laboratory: process of performing an experiment, from previous planning until the moment of leaving the bench. The workshop was divided in two parts: Introduction and overview to the Good Laboratory  Practices.Highly interactive and practical daily lab situations with real equipment. Upon completion of this workshop participants are able to understand the basics of good laboratory practices, plan an experiment[...]

U7-Nanotechnology Unit
Read More

U8. Micro – Nano Technology Unit

Ciber bbn

U8. Micro – Nano Technology Unit

  • Scientific Director: Dr. Rosa Villa rosa.villa@imb-cnm.csic.es
  • Scientific Coordinator: Dr. Xavier Illa xavier.illa@imb-cnm.csic.es
  • Entities: Instituto de Microelectrónica de Barcelona – Centro Nacional de Microelectrónica (IMB-CNM, CSIC)
  • Address: Campus UAB, 08193, Cerdanyola del Vallés, Barcelona, Spain
  • Phone: +34 935 947 700 ext. 1208
  • Web: IMB – CNM, CSIC

CNM CSIC

Order request

Description

This Micro-Nano Technologies Unit is located in the Microelectronic Institute of Barcelona, (IMB-CNM, CSIC) and it is coordinated by Dr. Rosa Villa.

The unit has the capacity for producing high quality CVD-graphene and, thanks to the integration of the unit in the clean room facilities of the IMB-CNM, it is possible to complete a wide range of micro- and nanofabrication processes (thermal processes and CVD, metallization, photolithography, dry and wet etching, etc.) for the complete fabrication of graphene-based microdevices. The unit also comprises the equipment that allow the fabrication of such devices in flexible substrates like Polyimide and Parylene to build biocompatible implants and neuroprosthesis. In addition, the unit has the capacity for the encapsulation and electrical characterization of the fabricated devices.

The clean-room facility of the IMB-CNM is the largest installation with micro-nano technologies facilities in Spain. Its 1500 m2 Clean Room classes 10 to 10,000 are part of the MICRONANOFABS network, considered as Singular Scientific-Technical Infrastructure (ICTS).

U8. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 696656
Graphene-based disruptive technologies — GrapheneCore1
Unión Europea (Comisión Europea) H2020-Adhoc-2014-20 Partner
GA: 785219 Graphene Flagship Core Project-2 — GrapheneCore2’
Unión Europea (Comisión Europea) H202-SGA-FET-GRAPHENE-2017 Partner
GA: 649953 GRAPHENE FPA – FLAGSHIP - Graphene-based revolutions in ICT and beyond Unión Europea (Comisión Europea) H2020-FETFLAG-2014 Partner
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
SAF2014-62114-EXP RUPTURE OF THE HEMATORRETINIAN BARRIER: CAUSE OR CONSEQUENCE OF THE DIABETIC RETINOPATHY? MINECO Others
BIO2014-61377-EXP BIOLIVER: THE DECONSTRUCTION APPLIED TO HEPATOLOGY MINECO Others
H2020-Adhoc-2014-20 - 696656 GrapheneCore1 European Commission Participant
FP7-ICT-2013-FET-F - 604391 Neurographene: Neurological Recordings with Graphene EUROPEAN COMISSION Others
IMI Grant agreement No 115902 Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS) Others

Publications

2016

  • Moya A., Sowade E., del Campo F.J., Mitra K.Y., Ramon E., Villa R. et al. All-inkjet-printed dissolved oxygen sensors on flexible plastic substrates. Organic Electronics: physics, materials, applications. 2016;39:168-176.
  • Yeste J., Illa X., Gutierrez C., Sole M., Guimera A., Villa R.. Geometric correction factor for transepithelial electrical resistance measurements in transwell and microfluidic cell cultures. Journal of Physics D: Applied Physics. 2016;49(37):-.
  • Hernando A., Lazaro J., Gil E., Arza A., Garzon J.M., Lopez-Anton R. et al. Inclusion of Respiratory Frequency Information in Heart Rate Variability Analysis for Stress Assessment. IEEE Journal of Biomedical and Health Informatics. 2016;20(4):1016-1025.

News U8

08 Mar

The revolutionary path of research in NANBIOSIS and advice on Woman’s Day 2024

Our interview series delve into the journeys of 7 female researchers, their challenges, and the call for gender equality in science, inspiring the next generation. March 8th 2024, NANBIOSIS (Spain) Kicking off on 11F “International Day of Women and Girls in Science” 2024, and spanning all the way until Woman’s Day 2024, our interview series has aimed to highlight the life, career and opinions of some of the brilliant minds within our network. Today is time to wrap it up, and for this reason we present you a summary of each of them and a chance to take a deeper[...]

18 Jul

ICTS participation in the First guide to facilitate the sustainable design of printed electronic devices

Scientists of NANBIOSIS Unit 8 have participated in the publication of a a comprehensive experimental review of inks, paper substrates, and printing techniques. The objective is to offer the scientific community a guide with data to facilitate the design of printed devices and manufacture them in an ecological way. Gemma Gabriel, researcher of Biomedical Applications Group at IMB-CNM and last author of the article, highlights the applications of the results in health monitoring, with non-invasive techniques such as glucose detection, although there are many applications where printed electronic materials and technologies are very useful. Among them, environmental monitoring, (in air[...]

03 Feb

“CIBER is collaboration”

CIBER Centro de Investigación Biomédica en Red (Consortium for Biomedical Research Network), one of the ICTS NANBIOSIS nodes to which 18 of its 26 units belong, presents the new institutional video “CIBER is Collaboration” This video puts a face to the scientific activity of CIBER researchers and highlights CIBER capacity for synergy. CIBER researchers speak about the main research lines of its 13 subject areas and highlights the collaboration between its more than 500 groups and more than 6,000 researchers belonging to more than 100 institutions of different natures that make up CIBER: hospitals, research centers, universities, foundations, etc. T[...]

25 May

“The almighty graphene”, a podcast by Elisabet Prats

Elisabet Prats Alfonso, a researcher in the team coordinating NANBIOSIS U8 Micro– Nano Technology Unit explains in a podcast her most recent research based on the functionalization of chemical and biochemical sensor platforms as well as the characterization of materials such as graphene for both neuronal recording and biomarker detection. Her work is part of the Graphene Flagship project in which she collaborates with relevant European groups. Eli Prat as a researcher Ph.D. in Chemistry and also dedicated to dissemination is a great exemple for the NANBIOSIS aim to encourage STEAM scientific vocations especially among girls. In addition, she is[...]

07 Apr

Researchers of NANBIOSIS U8 highlighted in the World Health Day

In the Picture: Gemma Gabriel and Rosa Villa World Health Day is celebrated every year on 7 April (on the aniversary of the World Health Organization constitution) to raise awareness about the ongoing health issues that concern people across the world. This year, Xarctec Salud has called the attention on patients with brain diseases and spinal cord injuries and has highlighted the GAB Lab. Biomedical Applications Group of the IMB-CNM-CSIC and CIBER-BBN, the group, led by Rosa Villa, coordinates unit 8 ICTS NANBIOSIS of Micro-nano Technology Unit. https://youtu.be/wiA5oFc6Q48 The Xartec Salut is a network, led by CREB UPC, made up of 47[...]

07 Jan

New graphene-based neural probes improve detection of epileptic brain signals

A study published in Nature Nanotechnology shows that flexible brain probes made of graphene micro-transistors can be used to record pathological brain signals associated with epilepsy with excellent fidelity and high spatial resolution. This research was led by the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the University College London Queen Square Institute of Neurology (UK). The ability to record and map the full range of brain signals using electrophysiological probes will greatly advance our understanding of brain diseases and aid the clinical management of patients with diverse neurological disorders. However, current technologies[...]

23 Dec

The suitability of flexible graphene depth neuralprobes for in vivo electrophysiology research

A study published in “Nature Nanotechnology” shows that flexible brain probes made of graphene micro-transistors can be used to record pathological brain signals associated with epilepsy with excellent fidelity and high spatial resolution. This research was led by the Catalan Institute of Nanoscience and Nanotechnology (ICN2), the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) and the University College London Queen Square Institute of Neurology (UK). Barcelona, Wednesday 22 December 2021. The ability to record and map the full range of brain signals using electrophysiological probes will greatly advance our understanding of brain diseases and aid the clinical management of patients wit[...]

20 Jul

Inkjet printing technology is driving innovation of sensors for point-of-care devices

Miguel Zea, researcher at GAB Group –  Nanbiosis U8 Micro– Nano Technology Unit  will defend hir PhD thesis on Friday 23 of July, at 11 am, at the Graus Room of the Faculty of Sciences and Biosciences of the UAB about “Inkjet printing technology is driving the innovation of sensors for point-of-care devices” Thesis directors: Gemma Gabriel and Eloi Ramon Further information and registration for the event, onñine, here Abstract:  The ‘Inkjet printing’ technology is called to be the next generation of flexible electronics capable of performing functions that were only accessible with state-of-the-art microfabrication technologies. This is due, in part, to the versatility of digital,[...]

U8-Micro-Nano Technology Unit
Read More

U9. Synthesis of Nanoparticles Unit

Ciber bbn

U9. Synthesis of Nanoparticles Unit

    • Entities: Instituto de Materiales y Nanociencia de Aragón (INMA)
    • Address: R&D Building, Campus Río Ebro, Universidad de Zaragoza. C/Mariano Esquirl S/n, 50018, Zaragoza, Spain
    • Phone: 34 976 761000 ext. 3496

Nanabiosis-logo Universidad de Zarargoza-U9-U13-U27.

Order request

Description

This unit, integrated in the Nanostructured Films and Particles Group at the Institute of Nanoscience and Materials of Aragón (INMA) coordinated by Dr. Jesús Santamaría, has as objective the synthesis of nanoparticles with applications in biomedicine. The unit provides an automated system for the synthesis of nanoparticles using laser-induced pyrolysis of chemical precursors in gas and/or aerosol phase, which enable either individual nanoparticles or biocompatible hybrid nanostructures to be produced in large quantities. In addition, this facility is able to draw on a wide range of nanoparticles fabrication technique, as well as having the necessary specialized personnel, to undertake exhaustive characterization of the microstructure, chemical composition, particles size and distribution of sizes, as well as magnetic, optical and colloidal properties and degree of biological functionality of the synthesized material.

U9. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
CTQ2014-52384-R INTELLIGENT APPLICATIONS BASED ON NANOSTRUCTURED FIBERS CONTAINING NATURAL BIOCIDES WITH PHARMACOKINETIC CONTROL OF THEIR RELEASE Ministerio de Economia y Competitividad Participant
CTQ2013-49068-C2-1-R MICROSYSTEMS BASED ON NANOSTRUCTURES WITH SPECIFIC PROPERTIES OF ADSORPTION AND SUPERFICIAL PLASMON, FOR DETECTION OF HIDDEN EXPLOSIVES AND AGENTS OF CHEMICAL WAR. Ministerio de Economia y Competitividad Participant
TARMAC TARMAC. New tools for the diagnosis and treatment of respiratory infectious diseases: pH-responsive matryoshka nanoparticles for an efficient and controlled intracellular delivery of oral antibiotics and gated nanoparticles for the detection of pathogenic microorganisms showing intracellular persistence Ministerio de Economia y competitividad Participant
TARMAC/IQMA-UDM-UPV pH-responsive matryoshka nanoparticles for an efficient and controlled intracellular delivery of oral antibiotics and gated nanoparticles for the detection of pathogenic microorganisms showing intracellular persistence CIBER-BBN-CIBERES-SEPAR Participant
H2020-MSCA-ITN-2016/H2020-MSCA-ITN-2016 European Training Network for Continuous Sonication and Microwave Reactors. Unión Europea Participant
H2020-SPIRE-2014-2015 ADREM / Adaptable Reactors for Resource- and Energy-Efficient Methane Valorisation Unión Europea Participant
I-2012/023 Development of a microfluidic platform to produce nanomaterials and assessment on new nanotechnology applications Unión Europea Participant
CTQ2016-77147-R NEW STRATEGIES FOR CO2 CONVERSION USING CATALYSTS UNDER ELECTROMAGNETIC RADIATION. MINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDAD Participant
CTQ2016-79419-R ADVANCED ADSORPTION TECHNOLOGIES, SERS DETECTION AND CATALYSIS FOR CHEMICAL WAR MINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDAD Participant
NANOHEDONISM A photo-triggered on-demand drug delivery system for chronic pain European Research Council Participant
I-2011/004 HECTOR- MICROWAVE-ASSISTED MICROREACTORS: DEVELOPMENT OF A HIGHLY EFFICIENT GAS PHASE CONTACTOR WITH DIRECT CATAYST HEATING Unión Europea Participant
FIS PI15/01118 Towards an advanced therapy of bone regeneration: tissue intermediates activated by infrared energy for the controlled expression of osteogenic and angiogenic factors INSTITUTO DE SALUD CARLOS III Others
AMBIT Animal Model of Bone Regeneration Induced by Tissue Intermediates Responsive to Near-Infrared Light Roche Farma Participant

Publications

2016

  • Sebastian V., Smith C.D., Jensen K.F.. Shape-controlled continuous synthesis of metal nanostructures. Nanoscale. 2016;8(14):7534-7543.

News U9

09 Apr

New cathalitic therapy for destroying key molecules within tumor cells

The prestigious journal Nano Letters published the work led by NANBIOSIS researchers, affiliated with Unizar, INMA (CSIC-UNIZAR), CIBER–BBN, and IIS Aragón. The successful development of this innovative treatment approach was possible through the efforts of our Unit 9, led by Prof. Santamaría and Dr. Hueso, both corresponding authors of the publication. As recently announced by Universidad de Zaragoza (Unizar), a team led by NANBIOSIS researchers at the Instituto de Nanociencia y Materiales de Aragón (INMA, a joint institute of CSIC and UNIZAR) has discovered a way to artificially conduct a new chemical reaction, called transamination. This approach can act within[...]

08 Mar

The revolutionary path of research in NANBIOSIS and advice on Woman’s Day 2024

Our interview series delve into the journeys of 7 female researchers, their challenges, and the call for gender equality in science, inspiring the next generation. March 8th 2024, NANBIOSIS (Spain) Kicking off on 11F “International Day of Women and Girls in Science” 2024, and spanning all the way until Woman’s Day 2024, our interview series has aimed to highlight the life, career and opinions of some of the brilliant minds within our network. Today is time to wrap it up, and for this reason we present you a summary of each of them and a chance to take a deeper[...]

26 Feb

Women in NANBIOSIS part 4: María Sancho’s journey from nanomaterials to cancer therapy

Our expert in nanocarriers talks about her journey from biotechnology to cancer therapy, an example of passion and perseverance in science. February 2024, I3A/CIBER-BBN, Zaragoza (Spain) The silence of the meeting room is only broken by the constant purring of the heating system. A large square table made of dark wood fills the entire room almost completely. Its dimensions are too extensive for anyone to reach its center. One may wonder, how many passionate conversations about the next step to take in countless research projects have been witnessed by these four walls? The door swings open briskly, and a familiar[...]

19 Feb

Women in NANBIOSIS part 2: Ana Martín, and her Multi-degree Journey

We ask Dr. Martín about her innovations in cancer treatment with nanoparticles, in the context of her collaborations with NANBIOSIS. This is part of a series of interviews to several female researchers within the context of International Day of Women and Girls in Science 2024 and Woman’s Day 2024. For more interviews, visit our news section here. February 2024, INMA-CSIC/CIBER-BBN, Zaragoza (Spain) We are walking through the tall corridors that connect the numerous blocks of the large R&D Building, located near the Río Ebro Campus of Unizar. This building is a conglomerate of institutes, laboratories, and research groups. In its[...]

07 Feb

Bringing Hope to Cancer Treatment: New Pioneering Advances in Nanotechnology

NANBIOSIS Researchers Lead the Way in Innovative Nanomedicine Approaches Cancer remains a formidable challenge globally, with 19.1 million cases diagnosed in 2020, resulting in nearly 10 million deaths. However, amidst these alarming statistics, a beacon of hope emerges from the field of nanomedicine. Spearheaded by Professor Jesus Santamaria and his team at the NFP group, part of the NANBIOSIS ICTS Unit 9, groundbreaking advancements in nanotechnology are revolutionizing cancer treatment. Funded by the European Research Council, their efforts mark a significant stride towards more effective and targeted therapies. “The potential adverse effects (of antineoplastic agents) on healthy cells is t[...]

08 Nov

Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.

2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed audience. On Tuesday 7 EHD and BBN sessions will specific for each area in separate rooms (with common coffee break). Posters of both areas were on display in the exhibit hall throughout the entirety of the Annual Meeting. Moreover, at the “Posters & beers” session (Monday[...]

12 Jul

Jesús Santamaría, Scientific Director of NANBIOSIS Unit 9, elected foreign member of the Istituto Lombardo Accademia di Science et Lettere

Jesús Santamaría, Professor of Chemical Engineering at the University of Zaragoza, has been elected a foreign member of the Istituto Lombardo Accademia di Science et Lettere, in its division of Mathematical and Natural Sciences, Chemistry section. This institution was originally founded by Napoleon Bonaparte in 1797, as the National Institute of the Cisalpine Republic, in charge of collecting discoveries and perfecting the arts and sciences, following the model of the Institut de France. Napoleon himself appointed the first members of the Institute and its first president, Alesssandro Volta, Italian chemist and physicist, famous primarily for the discovery of methane in[...]

11 Nov

Researchers of two NANBIOSIS units success in the Third Millennium Awards

Researchers of two NANBIOSIS units success in the Third Millennium Awards: the Young Research Talent award to Julia Ramirez (NANBIOSIS U27) and the Research and Future Award to the NFP group (NANBIOSIS U9) Last November 8, four initiatives received the highest award in the eighth edition of the HERALDO contest Third Millennium Awards which represent the recognition of the Aragonese community from the youngest to the most consolidated trajectories in knowledge transfer, innovation, and scientific dissemination. The Paraninfo of the University of Zaragoza hosted this event in which researchers CIBER-BBN – NANBIOSIS were recognised this year: The Films and Nanostructured[...]

U9-Synthesis of Nanoparticles Unit
Read More

U10. Drug Formulation

Ciber bbn

U10. Drug Formulation

    • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
    • Scientific Coordinator: Dr. Idoia Gallego Garrido idoiagallego@hotmail.com
    • Entities: Universidad del País Vasco (UPV/EHU)
    • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
    • Phone: +34 653593042
    • Fax: +34 945 013040
    • Web: NANOBIOCEL UPV/EHU

UPV-EHU

Order request

Description

Located at the Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Campus of Alava in Vitoria. The Unit is led by Prof. José Luis Pedraz and consists of large laboratories for cell culture, chromatography equipment, sample preparation and characterization, and one specific for scale preparation of pharmaceutical formulations. Recently the group has incorporated 3D bioprinters of the last generation with different technologies based on extrusion, inkjet, among others. It has also incorporated self-assembly equipment of nanoparticles based on microfluidic technologies.

This Unit can design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA, and vaccines using different methodologies based on micro and nano-medicine and the latter technology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this Unit. It counts on the most advanced equipment for micro and nanoencapsulation.

The Unit aims to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.

The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit10 counts with the most advanced equipment to cover the development for all the steps of the process.

One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency

U10. Services & Rates

Equipments

Active projects

  • Inhaled RNA Vaccines Against Tuberculosis. RTC: PMPTA/00143. Call: “Proyectos de I+D vinculados a la medicina personalizada y terapias avanzadas” from the joint initative ISCIII-CDTI. Funding agency: EU Next Generation Ministerio de Ciencia e Innovación CDTI. Duration: May 2024 – May 2026. Role: Partner.
  • Nanovectors for direct local-regional and controlled intravenous administration of antitumor drugs. Strategies to minimize adverse effects and maximize therapeutic response. ONCOLIBERYX. RTC: CPP2021-008362. Call: Convocatoria de ayudas para proyectos de colaboración público-privada 2021. Funding agency: Ministerio de Ciencia e Innovación. Duration: May 2022 – May 2024. Role: Partner.
  • Unlocking data content of Organ-On-Chips UNLOOC. RTC: 101140192-1. Call: HORIZON-KDT-JU-2023-1-IA-Topic-1. Funding agency: HORIZON Programme. Duration: January 2023 – May 2024. Role: Partner.
  • Optimization of a non-viral vector platform based on functionalized niosomes with nanodiamonds for gene therapy in cystic fibrosis. IP: Jose Luis Pedraz Muñoz and Gustavo Puras Ochoa. Funding agency: Ministerio de Ciencia e Innovacion. Funds: € 181.500. Duration: Jun 2020 – Jun 2023

Other projects

Title Fundin: Organism Call: Funding source Role
RTC-2016-4770-1 Development of a new bioadhesive for the treatment of Pterigium. Biotape
Ministerio de Economía, Industría y Competitividad (MINECO) Retos Colaboración 2016 Partner
RTC-2016-5451-1 Development of Bioprinting and Bioink systems for cartilage and bone repair
Ministerio de Economía, Industria y Competitividad (MINECO) Retos Colaboración 2016 Partner
GA: 783132 POSITION-II “A pilot line for the next generation of smart catheters and implants”
Electronic Component Systems for European Leadership Joint Undertaking (JU) - ECSEL JU H2020-ECSEL-2017-1-IA-two-stage Partner
GA: 645991 DRIVE – Diabetes-Reversing Implants for Enhanced viability and long-term efficacy Unión Europea (Comisión Europea) H2020-NMP-2014-two-stage Partner
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Ref Title Funding Organism Unit Role
RTC-2016-4770-1 DEVELOPMENT OF A NEW BIOADHESIVE FOR PTERIGIUM SURGERY. BIOTAPE MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. Participant
RTC-2016-5451-1 DEVELOPMENT OF BIOIMPRESSION SYSTEMS AND BIOTINES FOR THREE-DIMENSIONAL CARTILAGE AND BONE REGENERATION MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. Participant
RTC-2015-3303-1 Lipid solid nanoparticles for subcutaneous administration of antitumor marine compounds - UNDERLIPIDS MINISTERIO DE ECONOMIA Y COMPETITIVIDAD

Publications

2016

  • Grijalvo S., Puras G., Zarate J., Pons R., Pedraz J.L., Eritja R. et al. Nioplexes encapsulated in supramolecular hybrid biohydrogels as versatile delivery platforms for nucleic acids. RSC Advances. 2016;6(46):39688-39699.
  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Fleischer A. et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. International Journal of Pharmaceutics. 2016;498(1-2):263-273.
  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Bachiller D. et al. Stability study of sodium colistimethate-loaded lipid nanoparticles. Journal of Microencapsulation. 2016;33(7):636-645.
  • Garcia-Orue I., Gainza G., Gutierrez F.B., Aguirre J.J., Evora C., Pedraz J.L. et al. Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. International Journal of Pharmaceutics. 2016;:-.
  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. International Journal of Pharmaceutics. 2016;503(1-2):115-126.
  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials. 2016;77:267-279.

News U10

13 Nov

Rosa Hernández of the NanoBioCel group-NANBIOSIS U10 has received the Female Talent Award 2023 Women and Science

On Thursday, November 2, the Female Talent Award, in the category of Women and Science, was awarded to Rosa Hernández from the NanoBioCel group of CIBER BBN and the U10 Drug Formulation Unit. The award is given by AMPEA (Association of Professional and Business Women of Alava). In her award speech, Rosa Hernández, highlighted that [...]

08 Nov

Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.

2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed [...]

15 Oct

Developing Support Technologies for adressing traslational gaps in regenerative medicine.

On the 20th of October, CIBER-BBN group NanoBioCell – NANBIOSIS U10 Drug Formulation unit organises the Conference “Developping support technologies for adressing traslational gaps in regenerative medicine” by Dr. James-J Yoo. The Conference will take place in the Assembly hall of the Faculty of Pharmacy on Friday 20th of October, 2023 from 12:00 to 13:00, [...]

02 Oct

3D Printing and Bioprinting for Pharmaceutical and Medical Applications

Researchers of CIBER-BBN group NanoBioCell – NANBIOSIS U10 Drug Formulation unit Jose Luis Pedraz Muñoz, Laura Saenz del Burgo Martínez, Gustavo Puras Ochoa, Jon Zarate Sesma have edited the book “3D Printing and Bioprinting for Pharmaceutical and Medical Applications” The increasing availability and decreasing costs of 3D printing and bioprinting technologies are expanding opportunities to meet medical needs. 3D [...]

22 Jun

The role of microfluidics and 3D-bioprinting in the future of exosome therapy. A high impact review

Researchers of the NanoBioCel research group of the University of the Basque Country (UPV/EHU) and CIBER BBN, belonging to NANBIOSIS U10 Drug Formulation, Bioaraba, and CONICET Foundation of Argentina, have collaborated in a studio entitled: “The role of microfluidics and 3D-bioprinting in the future of the exosome therapy” which has been published in the journal [...]

23 Nov

Three articles acknoledging NANBIOSIS contribution awarded at the Bioaraba Research and Innovation Conference

Researchers of NANBIOSIS U10 “Drug Formulation” – NanoBiocel research group from CIBER-BBN and UPV/EHU receives 3 awards in the category of Best International Articles at the annual Bioaraba Research and Innovation Conference. On 4 November, the Bioaraba Health Research Institute held its XXIII Research and Innovation Conference in Vitoria. This important annual forum held in [...]

27 Oct

II Scientific Communication course

On October 18 and 19, was held the second course on Social Communication of Science, orgnized by NANBIOSIS U10 Drug Formulation Unit -(NanoBioCell Group of CIBER-BBN and UPV-EHU, this year entitled “Tools for the social communication of science“. The course aimed to provide doctoral students with communication with tools to be employed in their work [...]

09 Oct

The sprint of the European Project Moore4medical

The NanoBioCel group of the CIBER BBN, which also runs NANBIOSIS U10 Drug Formulation unit , organized the Workshop #6 of the Moore4medical European project at the Alava Technology Park on October 4, 5 and 6 The Central Building of the Álava Technology Park hosted the ‘Workshop #6’ of the European project which. 80 people [...]

29 Apr

CRISPR technologies for Cystic Fibrosis treatment

Cystic fibrosis is an inherited genetic disease that mainly affects the lungs and the digestive system On April 6, the first meeting was held, on the one hand, with people with Cystic Fibrosis and the Euskadi Cystic Fibrosis Association (Arnasa) and, on the other, with the NanoBioCel research group of the CIBER-BBN and the University [...]

05 Apr

1st Meeting with Cystic Fibrosis Patiens (NanoBioCel -ARNASA)

Cystic Fibrosis is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It is a genetic, degenerative and chronic disease, with a population incidence is 1 in 5,000, so it is considered among the so called “Rare Diseases” The most common symptoms are continuous colds, repeated infections, decreased lung capacity, impossibility of fat absorption and [...]

Read More

U12. Nanostructured liquid characterization unit

Ciber bbn

U12. Nanostructured liquid characterization unit

    • Scientific Director: Prof. Carlos Rodríguez cranqb@cid.csic.es
    • Scientific Coordinator: Jordi Esquena jemqci@iqac.csic.es
    • Entities: Colloid and Interfacial Chemistry Group (QCI) at the Institute of Advanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
    • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
    • Phone: +34 934 006 159
    • Web: QCI – IQAC- CSIC


IQAC CSIC


Order request

Description

The unit is located at the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), in Barcelona and it is coordinated by the Colloidal and Interfacial Chemistry Group, led by Dr. Carlos Rodríguez. The unit is focused on the characterization of nanostructures in liquids and liquid/liquid interfaces, such as micelles, liposomes, micro- and nano-emulsions, and nanoparticles. The unit features state-of-the-art instrumentation for the determination of various parameters such as size distribution and zeta potential (surface charge), critical micelle concentration (CMC), solubilization capacity, osmolarity, surface and interfacial tension, wettability, refractive index, turbidity, colloidal stability, density, viscosity and other rheological parameters (shear and elastic moduli, critical yield stress, etc.)

The Unit 12 has implemented and mantein the ISO9001 certification for standard quality control system.

IQNet ISO 9001:2015 Certification 

AENOR ISO 9001:2015 Certification 

U12. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
CTQ2014-52687-C3-1-P Design and applications of new biocompatible micro / nanogels obtained by advanced condensation methods (MICRONANOGELES) MINECO Participant
2014SGR1655 Grants for consolidated Research Groups of Catalonia Generalitat de Catalunya Participant
FP7-PEOPLE-2013-ITN - 606713 Biopolymer Based FOOd Delivery Systems (BIBAFOODS) Unión Europea Participant
Plan de Actuación 2015 Agreement of ACC1Ó with the UAB, the PRUAB, the CSIC and the CVC for the promotion of the technological transfer Generalitat de Catalunya Participant
TECSPR14-2-0033 Theranostic Magnetic Nanoparticles For Cancer Diagnosis and Treatment: Magnetic Properties and Controlled Release of Anticancer Drugs (TheraMagNano) Unión Europea Participant
TECSPR14-2-0044 Novel antimicrobial hydrogels for contact lenses (HYDROLENSES) Unión Europea Participant
Acción COST CM1101 Joint Meeting of WG 3 and WG 4. Workshop "Nano-biocolloidal materials and non-equilibrium self-assembly" Unión europea Participant
Ref.: 308810 076/2015 DEVELOPMENT OF INNOVATIVE FORMULATIONS FOR THE DELIVERY OF ACTIVITIES INTO THE SKIN (ES) ALMIRALL Participant

Publications

2016

  • Fornaguera C., Caldero G., Solans C.. Electrolytes as a tuning parameter to control nano-emulsion and nanoparticle size. RSC Advances. 2016;6(63):58203-58211.
  • Caldero G., Montes R., Llinas M., Garcia-Celma M.J., Porras M., Solans C.. Studies on the formation of polymeric nano-emulsions obtained via low-energy emulsification and their use as templates for drug delivery nanoparticle dispersions. Colloids and Surfaces B: Biointerfaces. 2016;145:922-931.
  • Fornaguera C., Feiner-Gracia N., Caldero G., Garcia-Celma M.J., Solans C.. PLGA nanoparticles from nano-emulsion templating as imaging agents: Versatile technology to obtain nanoparticles loaded with fluorescent dyes. Colloids and Surfaces B: Biointerfaces. 2016;147:201-209.
  • Magana J.R., Kolen’Ko Y.V., Deepak F.L., Solans C., Shrestha R.G., Hill J.P. et al. From Chromonic Self-Assembly to Hollow Carbon Nanofibers: Efficient Materials in Supercapacitor and Vapor-Sensing Applications. ACS Applied Materials and Interfaces. 2016;8(45):31231-31238.
  • Perez-Carrillo L.A., Vilchez S., Mosa J., Aparicio M., Castro Y., Duran A. et al. Synthesis and properties of TiO2-P2O5 and SiO2-TiO2-P2O5 porous hybrids obtained by templating in highly concentrated emulsions. Ceramics International. 2016;42(16):18965-18973.

News U12

08 Mar

The revolutionary path of research in NANBIOSIS and advice on Woman’s Day 2024

Our interview series delve into the journeys of 7 female researchers, their challenges, and the call for gender equality in science, inspiring the next generation. March 8th 2024, NANBIOSIS (Spain) Kicking off on 11F “International Day of Women and Girls in Science” 2024, and spanning all the way until Woman’s Day 2024, our interview series has aimed to highlight the life, career and opinions of some of the brilliant minds within our network. Today is time to wrap it up, and for this reason we present you a summary of each of them and a chance to take a deeper[...]

01 Mar

Women in NANBIOSIS part 5: Susana Vílchez and her insights on water-in-water emulsions and gender equality in Science

Dr. Vílchez, our esteemed colloidal chemistry researcher, discusses her focus on water-in-water emulsions and microcoacervates. She highlights gender biases in science and advocates for inclusivity and recognition of women’s contributions. This is part of a series of interviews to several female researchers within the context of International Day of Women and Girls in Science 2024 and Woman’s Day 2024. For more interviews, visit our news section here. March 2024, IQAC-CSIC, Barcelona (Spain) Dr. Susana Vílchez, an esteemed researcher in colloidal chemistry, and the technical and quality manager of Unit 12 of NANBIOSIS, offers a profound insight into her research endeavors[...]

06 Feb

‘Magic Bullets’ Against Cancer: Unveiling the Potential of DNA Nanoparticles

DNA nanoparticles to selectively target tumor tissues through precise control of the synergies between transported drugs. February 2024, IQAC-CSIC/CIBER-BBN, Barcelona. The team led by Drs. Carme Fàbrega and Ramón Eritja, in close collaboration with 3 units of the NANBIOSIS ICTS, has developed a new strategy to improve the efficacy and reduce the toxicity of anticancer drugs. They have chemically linked several cytotoxic drugs, currently used in the treatment of various types of tumors, to DNA nanostructures. These structures selectively target cancerous tissues through folate receptors. This tactic allows precise control of drug concentration and exploits their combined effect. The results[...]

25 Sep

Carlos Rodriguez-Abreu (NANBIOSIS U12) keynote speaker at the European Colloid and Interface Society ECIS 2023

Carlos Rodriguez-Abreu, Scientific Director of NANBIOSIS U12 Nanostructured liquid characterization unit  gave a Keynote presentation entitled “Chromonic liquid crystal emulsions” at the European Colloid and Interface Society ECIS 2023 conference held in Naples, Italy (September 3-8, 2023) . Chromonic liquid crystals (CLC) can be used as templates for material synthesis and, since some CLC are nontoxic and water-based, they are also interesting for biological and medical applications. The presentation included a summary of experimental results on internally structured emulsions made of CLC encapsulated in droplets, that feature various complex morphologies. Photothermal, sensing and imaging applications are envisaged.[...]

15 Nov

Happy Day of Chemistry! The role of Chemistry in a sustainable research in health

Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

03 May

OPEN SUBMISSION FOR JOURNAL SPECIAL ISSUE ON OLIGONUCLEOTIDE BASED THERAPIES

Dr. Ramon Eritja, Scientific Director of NANBIOSIS unit 29 of Oligonucleotide Synthesis Platform (OSP) and Dr. Santiago Grijalvo researcher at NANBIOSIS unit 12 of Nanostructured liquid characterization, from CIBER-BBN and IQAC-CSIC, together with Dr. Andreia F. Jorge, from Coimbra Chemistry Centre (CQC), acting as guest editors of journal Pharmaceutics, of MDPI Publisher, welcome authors to submit their articles on special issues on Recent Trends in Oligonucleotide Based Therapies. In the past few decades, significant efforts have been made towards the clinical application of oligonucleotides. However, the potential of the therapeutic applications of RNA-based strategies have recently been spotlighted after the first approval of mRNA vaccines in response to COVID-19[...]

02 May

Wide representation of NANBIOSIS research in NALS 2022 and best Oral Presentation to Eloi Parladé

During the last 27-29 April, the 3rd International Conference on Nanomaterials Applied to Life Sciences 2022 (NALS 2022) has taken place in the Excellence Campus of Universidad de Cantabria in Santander (Spain), organized by the University of Cantabria and Institute Valdecilla-IDIVAL. NALS 2022 has been a multidisciplinary conference series sharing new results and ideas in the fields of biosensors, lab on a chip, drug delivery nanopharmacy. nanobiotechnology, intelligent nanomaterials, magnetic materials, nanotoxicity, antimicrobials, novel applications of 3d bioprinting and nanoimaging. NANBIOSIS has been represented at this edition by members of several of its units, among them we must highlight the set of four ora[...]

U12-Nanostructured liquid characterization unit
Read More

U14. Cell Therapy

JUMISC

U14. Cell Therapy

  • Scientific Director: Dra. Esther López Nieto elopez@ccmijesususon.com
  • Entities: Jesus Uson Minimally Invasive Surgery Centre (JUMISC)
  • Address: Carretera N-521, km 41, 10071 Cáceres
  • Phone: + 34 927 181 032
  • Web: JUMISC

Order request

Description

Laboratory with an area of 81,02 m2 for cell biology and molecular biology techniques. The laboratory is also equipped with two cell culture rooms for the isolation, expansion and characterization of different cell types.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

U14-Cell Therapy
Read More